⚠ Substantial Equivalence Is a Door, Not a WallModerate threat
Intuitive Surgical (ISRG) — threat to the moat
A competitor does not have to prove its robot is better. It has to show it is equivalent to a da Vinci.
The regulatory moat around surgical robotics is thinner than the technology suggests, and Intuitive's own description of the pathway is the evidence.
Its products are Class II devices subject to premarket notification under section 510(k). To obtain clearance, a manufacturer "must submit to the FDA a premarket notification submission" showing that the proposed device is substantially equivalent to a legally marketed predicate device1. Class II devices are subject to general controls plus special controls — performance standards, post-market surveillance, patient registries, guidance documents2 — but not to the premarket approval regime reserved for the highest-risk devices.
The practical effect is that a competitor does not need to prove its robot is better, or even prove it works in a randomised trial. It needs to show equivalence to something already cleared, and da Vinci is the predicate.
That is not the whole barrier. Each procedure indication requires its own clearance in each jurisdiction, and Intuitive has spent two decades collecting them — the 10-K's regulatory section runs to pages of specific approvals across the United States, Korea, Japan, Europe, Taiwan and China3. Nor does clearance produce adoption: a cleared robot with no clinical evidence and no trained surgeons sells nothing.
But it does mean the regulatory question is a matter of time and money rather than of possibility, which is a different kind of moat from a patent monopoly or a state licence.
Watch the rate at which competitors obtain indications rather than clearances. A rival cleared for general laparoscopic use is a press release; a rival reimbursed and cleared for prostatectomy in Japan is a competitor.
- ReportedTo obtain clearance, a manufacturer "must submit to the FDA a premarket notification submission demonstrating that the proposed device is 'substantially equivalent' to a legally marketed predicate device".Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedClass II devices are subject to general controls plus special controls — performance standards, post-market surveillance, patient registries, guidance documents — but not to the premarket approval regime reserved for the highest-risk...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedEach procedure indication requires its own clearance in each jurisdiction, and Intuitive has spent two decades collecting them — the 10-K's regulatory section runs to pages of specific approvals across the United States, Korea, Japan,...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗